JAMA Research Letter
Journal of the American Medical Association, November 14, 2023
A cohort study based on a random sample of 16 million patients in the PharMetrics Plus database, a large health claims database that captures 93% of all out-patient prescriptions and physician diagnoses in the U.S.
What’s Interesting about this article?
- Studies have found increased risks of gastrointestinal adverse events (biliary disease, pancreatitis, bowel obstruction and gastroparesis) in patients with diabetes who take GLP-1 agonists.
- Diabetics have a higher baseline risk for adverse GI effects and studies are lacking for normal adults taking this class of drugs for weight loss, so risk in latter group not known.
- This study found that use of GLP-1 agonists for weight loss, in comparison with use of bupropion-naltrexone, was associated with increased risk of pancreatitis, gastroparesis and bowel obstruction, but not biliary disease.
- Doctors and patients without diabetes should be aware of adverse GI effects with the use of GLP-1 agonists.
- Large, randomized-controlled studies will be needed to establish risk of adverse GI effects with use of GLP-1 agonists in obese individuals without diabetes. However, since these adverse effects can be quite serious, caution should be used in using this class of drugs in normal adults.
- Risk-Benefit analysis GLP-1 agonists in obese individuals should balance significant weight loss of 20-30 % with cost of drugs, life-time commitment, and side effects.
Disclaimer: Article of the Week selections by JournalDoc physicians are independent, unbiased and have no commercial conflict of interest. JournalDoc does not support or endorse the findings or opinions expressed in the article. Findings in the article may need to be supported by further research and/or the consensus of experts.